Group structure
9 companies in 4 countries
Loading your page…
Loading your page…
9 companies in 4 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1–25 of 52
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Calcitonine-EssPharma 100 IE/ml, oplossing voor injectie en infusieOplossing voor injectie, Oplossing voor infusie | Calcitonin (salmon synthetic) | Netherlands | Authorised | 1977 |
| Camcolit-250, tabletten 250 mgTablet | Lithium | Netherlands | Authorised | 1982 |
| Camcolit-400, tabletten 400 mgTablet | Lithium | Netherlands | Authorised | 1982 |
| Clobazam Essential Pharmaceuticals 1 mg/ml, suspensie voor oraal gebruikSuspensie voor oraal gebruik | Clobazam | Netherlands | Authorised | 2022 |
| COLOBREATHEPolvere per inalazione, capsula rigida | Colistin | Italy | Authorised | |
| Colobreathe | Colistin | EU (EMA) | Authorised | 2012 |
| Colobreathe 1.662.500 IE inhalatiepoeder, harde capsulesInhalatiepoeder in harde capsule | Colistin | Netherlands | Authorised | 2012 |
| Colobreathe 1.662.500 UI polvo para inhalacion, capsulas duras125 mg · Polvo para inhalación (cápsula dura) | Colistin | Spain | Authorised | 2013 |
| Colobreathe 1.662.500 UI polvo para inhalacion, capsulas duras125 mg · Polvo para inhalación (cápsula dura) | Colistin | Spain | Marketed | 2014 |
| Flammacerium 1% / 2,2% crèmeCrème | Cerium nitraat, Silver sulfadiazine | Netherlands | Authorised | 1983 |
| Flammazine, crème 1%Crème | Silver sulfadiazine | Netherlands | Authorised | 1973 |
| GALANTAMINE ER24 mg · Capsule (Extended-Release) | Galantamine | Canada | Marketed | 2011 |
| GALANTAMINE ER8 mg · Capsule (Extended-Release) | Galantamine | Canada | Marketed | 2011 |
| GALANTAMINE ER16 mg · Capsule (Extended-Release) | Galantamine | Canada | Marketed | 2011 |
| HALDOLSoluzione iniettabile | Haloperidol | Italy | Authorised | |
| Haldol 2 mg/ml, drankDrank | Haloperidol | Netherlands | Authorised | 1972 |
| HALDOL DECANOASSoluzione iniettabile | Haloperidol | Italy | Authorised | |
| Haldol decanoas oplossing voor injectie 100 mg/ml, oplossing voor injectieOplossing voor injectie | Haloperidol | Netherlands | Authorised | 1982 |
| Haldol decanoas oplossing voor injectie 50 mg/ml, oplossing voor injectieOplossing voor injectie | Haloperidol | Netherlands | Authorised | 1981 |
| Haldol oplossing voor injectie 5 mg/ml, oplossing voor injectieOplossing voor injectie | Haloperidol | Netherlands | Authorised | 1972 |
| Haldol tabletten 10 mg, tablettenTablet | Haloperidol | Netherlands | Authorised | 1981 |
| IOPIDINE0.5 % / w/v · Solution | Apraclonidine | Canada | Marketed | 1995 |
| IOPIDINE1 % / w/v · Solution | Apraclonidine | Canada | Marketed | 1992 |
| IOPIDINECollirio, soluzione | Apraclonidine | Italy | Authorised | |
| Iopidine 1,0% 10 mg/ml, oogdruppels, oplossingOogdruppels, oplossing | Apraclonidine | Netherlands | Authorised | 1996 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Netherlands | 19 | 19 | 0 | CompaniesAll medicines |
| Canada | 13 | 7 | 6 | CompaniesAll medicines |
| Spain | 11 | 11 | 0 | CompaniesAll medicines |
| Italy | 8 | 8 | 0 | CompaniesAll medicines |
| European Union (EMA) | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of France, United Kingdom, United States
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; October 2026 register, published 7 October 2026; https://assets.publishing.service.gov.uk/media/6ac660fdec9d3aba1e0139d9/MS_Register_-_October_2026.csv; acquired 2026-10-13T22:59:02.704630+00:00; CSV-to-role/site projection is an adaptation under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; Crown copyright MHRA factual register
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; October 2026 published list; https://assets.publishing.service.gov.uk/media/6ac65fc6f1ba855cc196a8ba/New_Manufacturing_and_Wholesale_Dealer_Licences_-_October_2026.csv; acquired 2026-10-14T16:17:18.644817+00:00; CSV-to-licence-event projections are adaptations under OGL v3.0.
Licence: Open Government Licence v3.0; Crown copyright MHRA published licence history
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.